54 results about "Secretory cell" patented technology

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention relates to the field of microorganisms, in particular to lactobacillus plantarum TRT-01 with anti-inflammatory and bacteriostatic functions as well as a preparation method and application of the lactobacillus plantarum TRT-01, the lactobacillus plantarum TRT-01 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32237, and the preservation date is October 17, 2024. The plant lactobacillus has broad-spectrum bacteriostatic activity on 10 pathogenic bacteria such as helicobacter pylori, streptococcus mutans and the like, and can regulate Th1 / Treg immune balance and relieve inflammatory response by inducing dendritic cells to secrete cell factors IL-10 and IL-12, inducing T cells to secrete cell factors TGF-beta and IFN-gamma and inhibiting secretion of cell factors IL-6 at the same time. Therefore, the plant lactobacillus TRT-01 disclosed by the invention can be used for preparing a composition with anti-inflammatory and bacteriostatic effects, is suitable for the fields of medicines, foods, health-care products and the like, and is particularly suitable for developing a microbial preparation with a probiotic effect.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The invention relates to an up-regulation Nuak1 immune cell and application thereof, and particularly provides an over-expression Nuak1 immune cell and application thereof in preparation of drugs for treating diseases. Specifically, up-regulation of the Nuak1 in immune cells can significantly improve the toxicity, proliferative activity and cytokine or GZMB secretion ability of the immune cells, and further has the effect of enhancing tumor treatment.

The invention relates to a functionalized cartilage tissue repair material as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering. The invention aims to solve the problems that the existing decalcified bone matrix is insufficient in cartilage induction in cartilage repair, and is easy to cause blood vessel ingrowth and fibrosis repair. The preparation method comprises the following steps: inoculating cartilage cells on a three-dimensional porous frame structure carrier, carrying out in-vitro dynamic pre-culture to enable the cartilage cells to secrete an extracellular matrix, and carrying out decellularization treatment to obtain the functionalized cartilage tissue repair material retaining the cartilage specific matrix. The material has a suitable pore structure and abundant II-type collagen deposition, can effectively promote chondrocyte differentiation and hyaline cartilage regeneration, inhibits blood vessel ingrowth, maintains a cartilage vascular-free microenvironment, significantly improves the structure and function reconstruction effect of cartilage defect repair, and has good biocompatibility and clinical transformation potential.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The present application relates to the technical field of biological medicine, in particular to an anti-CEACAM5 antibody and application thereof, the anti-CEACAM5 antibody has the following technical features: the heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No.1, CDR-H2 with the amino acid sequence shown in SEQ ID No.2 and CDR-H3 with the amino acid sequence shown in SEQ ID No.3.The anti-CEACAM5 antibody has high affinity, is used as an antigen binding domain to construct a chimeric antigen receptor, and utilizes the chimeric antigen receptor to prepare a CAR-T cell, the CAR-T cell has killing activity on tumor cells positive for CEACAM5, and after co-culturing with CEACAM5-positive cells, the CAR-T cell can efficiently secrete the cytokine IFN-gamma, the nanobody can be effectively applied to immunotherapy, and has important significance for developing tumor treatment drugs.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-10 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-10 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-10, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

The present application belongs to the field of biomedical technology, and particularly relates to a cell-derived extracellular matrix and a preparation method and application of a cell culture plate coated with the cell-derived extracellular matrix. The present application cultures human astrocytes in a cell culture plate, and makes the human astrocytes secrete extracellular matrix. After the human astrocytes are added into a cell lysate for cell removal treatment, nucleic acid fragmentation treatment is performed to obtain the cell-derived extracellular matrix. The present application has relatively simple operation, short time period, and can realize batch production of extracellular matrix without external virus carrying and stable components. The obtained cell-derived extracellular matrix is resistant to storage, has good stability, is highly similar to a natural brain environment when coated on a cell culture plate, has good biocompatibility with cells, can be applied to tissue repair and regeneration as an ideal biomedical material, can regulate the progress and efficiency of human dermal fibroblast HDF transdifferentiation into neurons, and can obtain in-vitro survival neurons.

The invention belongs to the field of antibodies, and particularly relates to a bispecific antibody and application thereof. The bispecific antibody comprises a first antigen binding region and a second antigen binding region, wherein the first antigen binding region has HLA-G binding activity; and a second antigen binding region, the second antigen binding region having CD3 binding activity; wherein the first antigen binding region comprises an anti-HLA-G antibody, the anti-HLA-G antibody comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-3 or an amino acid sequence in a conservative modification form of the at least one selected from SEQ ID NO: 1-3. The bispecific antibody can be combined with CD3 and HLA-G so as to promote T cell activation, proliferation and cytokine secretion and effectively promote PBMC to kill tumor cells, and the bispecific antibody has good anti-cancer activity; and the bispecific antibody has low binding activity with T cells and high binding activity with tumor cells, and has good clinical application value and drug development value.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

Provided is a technique capable of evaluating a property of a secretion product with high accuracy.　Specifically provided are a secretion product evaluation method and others, the secretion product evaluation method comprising: a positional information identification step for identifying positional information of at least one secretory cell and at least one antigen-holding particle on the basis of optical information relating to a carrier that holds the secretory cell and the antigen-holding particle; a secretion product information acquisition step for acquiring information relating to a secretion product that binds to a binding target molecule held by the secretory cell and the antigen-holding particle; and a secretion product evaluation step for evaluating a property of the secretion product on the basis of the positional information and the information relating to the secretion product.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The present invention discloses a recombinant type VII collagen protein, Pro.C7, whose amino acid sequence is shown in any one of SEQ ID NOs. 1-8. Also disclosed are its encoding gene, expression vector, host bacteria, preparation method, and application. The present invention designs recombinant human type VII collagen based on a partial sequence of human type VII collagen. The protein is expressed in prokaryotes, and the expression system is mature. The purified protein has been experimentally verified to be non-cytotoxic. By organizing laminin, it promotes fibroblast migration and cytokine secretion, participates in skin damage and repair, and can be used as a biomaterial in cosmetic products, among other applications.

The application discloses an anti-DLL3 nanobody, related products and purposes. The nanobody comprises a heavy chain variable region of CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is shown in one of SEQ ID No. 1-SEQ ID No. 6; the amino acid sequence of the CDR2 is shown in one of SEQ ID No. 7-SEQ ID No. 12; and the amino acid sequence of the CDR3 is shown in one of SEQ ID No. 13-SEQ ID No. 18. The anti-DLL3 nanobody of the application only comprises a heavy chain variable region, can specifically recognize a DLL3 antigen on a cell surface, the constructed CAR-T cell has killing activity on tumor cells positive to DLL3, can efficiently secrete a cytokine IFN-gamma, can be effectively applied to immunotherapy, and has important significance for developing tumor treatment drugs.

Provided are a dual-epitope CAR and dual-epitope CAR-T cell targeting CLL1, and the use thereof. The amino acid sequences of a chimeric antigen receptor and a fusion protein are SEQ ID NO: 1 and SEQ ID NO: 3, respectively. The dual-epitope CAR-T cell can secrete T cell-specific effector molecule IFN-γ and specifically kill CLL1+ target cells, and has tumoricidal activity in vivo. The present application can be used in the immunotherapy of CLL1 target-associated diseases.

This invention provides a method for modeling a fracture healing model under the influence of macrophages. The steps are as follows: Step 1: Establish a mathematical model of fracture healing based on the ordinary differential equation of fracture healing; Step 2: Establish a fracture healing model under the influence of macrophages based on the regulatory effects of macrophages and their secreted cytokines on bone tissue cells. This invention provides a mathematical description of the complex process of fracture healing based on the interaction between the immune system and bone tissue cells in the human body, and has theoretical guiding significance for studying the mechanism of fracture healing and treating fractures.

The utility model belongs to the field of biotechnology, and particularly relates to a device for preparing a multi-layer cell sheet, which comprises a clamp and a culture box for placing the clamp, the clamp comprises a clamp cover plate and a clamp base. The clamp cover plate is connected to the upper portion of the clamp base. The clamp cover plate is provided with a plurality of cover plate hollowed-out openings, the clamp base is provided with a plurality of base hollowed-out openings, and the cover plate hollowed-out openings and the base hollowed-out openings in the same position are the same in shape. Limiting structures are arranged on the four edges of the clamp base, and the cell sheets are pressed between the limiting structures by the clamp cover plate and then fixed between the clamp cover plate and the clamp base. Compared with the prior art, the positions of the cell sheets in the clamp can be fixed through the cell sheet fixing pieces, the cell sheets are kept in contact in the culture process, then intercellular connection is generated or extracellular matrixes are secreted, and multiple layers of cell sheets are prepared at a time under the condition of not depending on exogenous extracellular matrixes.

The invention discloses application of volatile components of Chuzhou chrysanthemum in preparation of medicines for treating depression and cognitive impairment. The volatile component of the Chuzhou chrysanthemum can be applied to preparation of drugs for treating depression; or preparing a medicine for treating cognitive impairment; or preparing a medicine for protecting neuroendocrine cells; or preparing medicines for treating nervous system diseases. The active ingredients are completely derived from the traditional medicinal plant Chuzhou chrysanthemum, and cell experiments prove that the active ingredients are non-toxic to nerve cells under the effective concentration (less than or equal to 50 mu g / mL) and can antagonize the damage effect of CORT. And compared with a synthetic drug, the anticipated side effect is smaller, and the patient compliance is better. According to the invention, it is found through molecular docking that Z-alpha-trans-bergamot alcohol and bornyl isovalerate have very strong binding activity with core targets EGFR and MAOB for the first time, the two compounds can be deeply developed as brand new lead compounds for treating neurological and mental diseases, and drug sources are expanded.

To provide a food and drink composition which has an excellent effect of promoting secretion of brain-derived neurotrophic factor (BDNF) from small intestinal endocrine cells from safe food materials.SOLUTION: There is provided a food and drink composition for promoting BDNF secretion from small intestinal endocrine cells containing 4'-demethylnobiletin as an active ingredient. The food and drink composition of the present disclosure may have an effect of reducing stress or depression in daily life, and alleviating anxiety, an effect of increasing vitality, energy or motivation, and / or an effect of reducing stomach discomfort or constipation in daily life. Since 4'-demethylnobiletin can be obtained by conversion from nobiletin of a citrus peel component by a koji mold fermentation method, the food and drink composition of the present disclosure is highly safe and has no concerns about side effects.SELECTED DRAWING: Figure 2

Relates to an application of an anti-TSLP antibody or an antigen-binding fragment thereof and a nucleic acid molecule encoding the antibody in preparation of drugs for preventing and / or treating asthma, allergic inflammation, anaphylaxis or autoimmune diseases, the antibody or the antigen-binding fragment thereof has high affinity to TSLP, can effectively bind to TSLP and block the proliferation effect of TSLP on Ba / F3-hTSLPR-hIL7R alpha cells, and can be used for preparing drugs for preventing and / or treating asthma, allergic inflammation, anaphylaxis or autoimmune diseases. And the TSLP is capable of blocking the activation of PBMC (peripheral blood mononuclear cells) and secreting cytokines.

To provide single hormonal insulin producing cells differentiated from pluripotent stem cells, and an in vitro method for differentiation.SOLUTION: The present invention provides an in vitro differentiated population of pancreatic endoderm cells obtained from the stepwise differentiation of pluripotent cells, wherein cells at each step of differentiation are cultured in medium comprising 5 mM to 20 mM glucose.SELECTED DRAWING: None

The invention relates to the technical field of biology, and particularly discloses a construction method of composite artificial dermis containing living cells, which comprises the following steps: S1, bracket pretreatment; s2, inoculating fibroblasts; s3, constructing a corium layer; s4, inoculating keratinocytes; s5, carrying out gas-liquid interface culture; s6, performing histological evaluation; according to the constructed dermis, the layers are distinct, the structures are bionic, fibroblasts and keratinocytes are constructed on the same support in a layered mode, the dermis layer and the epidermis layer are mutually coupled, and the morphological structure and the histological structure are similar to those of natural skin; the method has the advantages that cell activity is high, adhesion and proliferation are good, the pretreated hydrated scaffold promotes cell adherence and three-dimensional proliferation, fibroblasts secrete a large amount of extracellular matrixes in the scaffold, keratinocytes are efficiently differentiated under a gas-liquid interface condition, and good proliferation and differentiation activity is maintained.

This invention discloses a type B influenza virus T4 peptide that can induce cellular immune responses and its applications, belonging to the fields of immunotherapy and immunoassay technology. The immunogenicity of this long peptide (SEQ ID NO.1, named T4) was verified in 21 volunteers using ELISpot assay. Results showed that T4 was positive in 5 individuals, with a positive rate of 23.81%. ELISpot assay of human PBMCs (IFN-γ secretory cells) showed that T4 induced an immune response of up to 3060 SFCs / 10 in the population. 6 PBMC. Therefore, this peptide has good immunogenicity and universality in the population, and can be used as a specific detection peptide for monitoring cellular immune levels. At the same time, this peptide can effectively activate the T cell immune response in the population, and has the potential to be used as a candidate vaccine epitope peptide for the design of novel vaccines.

Described herein are compositions and methods for potent and long-lasting gene editing in a cell. The gene editing may result in an increase in function of a gene product. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. The presently disclosed compositions comprise a lipid composition, which can comprise an ionizable cationic lipid, a sterol, a phospholipid, and a selective organ targeting lipid. Also described herein are methods for treating a disease or disorder, such as a lung disease or disorder, involving the presently disclosed compositions.

Provided are a BCMA-targeting single-domain antibody, a chimeric antigen receptor, and a use thereof. Specifically provided are a BCMA-targeting single-domain antibody BCMA-VHH#81, a dual-epitope chimeric antigen receptor containing two different single-domain antibodies, a BCMA CAR-T cell, and a use thereof. The single-domain antibody BCMA-VHH#81 has high affinity. The BCMA CAR-T cell developed on the basis of the single-domain antibody BCMA-VHH#81 can well secrete T cell-specific effector molecule IFN-γ, can effectively specifically kill BCMA+ target cells, has good in-vivo tumor killing activity, and can not only significantly inhibit the proliferation of tumor cells in mice but also significantly prolong the survival time of the mice. The BCMA CAR-T cell has good anti-tumor ability, can be used in immunotherapy for BCMA-target-related diseases, and has wide clinical application prospects.

CD40 activating proteins comprising recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand are provided. The CD40 activating proteins may further comprise at least one antigen. Uses for the CD40 activating proteins include inducing immune responses directed to delivered antigens such as viral or cancer antigens. Properties of the CD40 activating protein may include the ability to induce proliferation of B cells or secretion of cytokines, such as IL-6, IL-12 and / or IL-15.

An in vitro method of preparing insulin-producing cell clusters for transplantation into a subject, comprising (a) seeding pancreatic progenitor cells onto a three-dimensional, porous scaffold at a seeding density greater than about 12.5 million cells per cm3 of scaffold and less than about 150 million cells per cm3 of scaffold, wherein the scaffold comprises a plurality of pores having an average pore diameter greater than about 225 μm and less than about 550 pm, and (b) culturing the cells on the scaffold for more than about 3 days in culture medium to obtain insulin-producing cell clusters within the pores of the scaffold for transplantation into a subject. In exemplary aspects, the pancreatic progenitor cells are cells derived from pluripotent stem cells.